253 related articles for article (PubMed ID: 6356608)
1. Doxorubicin (adriamycin) cardiomyopathy.
Saltiel E; McGuire W
West J Med; 1983 Sep; 139(3):332-41. PubMed ID: 6356608
[TBL] [Abstract][Full Text] [Related]
2. Adriamycin-induced myocardial toxicity: new solutions for an old problem?
Outomuro D; Grana DR; Azzato F; Milei J
Int J Cardiol; 2007 Apr; 117(1):6-15. PubMed ID: 16863672
[TBL] [Abstract][Full Text] [Related]
3. [Fatal myocardiopathy due to adriamycin in spite of a reportedly non-dangerous cumulative dose].
Battin J; Richir C; Bui NB; Hehunstre JP; Abecassis S
Ann Pediatr (Paris); 1989 Feb; 36(2):136-40. PubMed ID: 2930128
[TBL] [Abstract][Full Text] [Related]
4. [Cardiomyopathy due to adriamycin: the possibility of its prevention. Monitoring by noninvasive technics].
Bianchi L; Bertocchi C; Felci U; Ferrario G; Giani P; Mariani L; Medolago G; Sarti E
Minerva Med; 1989 Mar; 80(3):215-26. PubMed ID: 2717043
[TBL] [Abstract][Full Text] [Related]
5. Prenylamine inhibition of adriamycin-induced cardiomyopathy in mice.
Milei J; Bolomo NJ; Marantz A
Medicina (B Aires); 1982; 42(4):409-14. PubMed ID: 15171023
[No Abstract] [Full Text] [Related]
6. Abrogation of adriamycin-induced cardiotoxicity by selenium in rabbits.
Dimitrov NV; Hay MB; Siew S; Hudler DA; Charamella LJ; Ullrey DE
Am J Pathol; 1987 Feb; 126(2):376-83. PubMed ID: 3826299
[TBL] [Abstract][Full Text] [Related]
7. [Daunomycin-and adriamycin-induced cardiomyopathy--relationship between dosage of drugs and histopathological findings (author's transl)].
Yamaguchi H; Toyota S; Takahara O; Ichimaru M
Rinsho Ketsueki; 1978 Aug; 19(8):1041-50. PubMed ID: 713049
[No Abstract] [Full Text] [Related]
8. Adriamycin cardiomyopathy. Fatal outcome of general anaesthesia in a child with adriamycin cardiomyopathy.
McQuillan PJ; Morgan BA; Ramwell J
Anaesthesia; 1988 Apr; 43(4):301-4. PubMed ID: 3377152
[TBL] [Abstract][Full Text] [Related]
9. Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
Bjelogrlic SK; Radic J; Radulovic S; Jokanovic M; Jovic V
Exp Biol Med (Maywood); 2007 Dec; 232(11):1414-24. PubMed ID: 18040065
[TBL] [Abstract][Full Text] [Related]
10. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
Mohamed HE; Asker ME; Ali SI; el-Fattah TM
J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
[TBL] [Abstract][Full Text] [Related]
11. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy.
Mason JW; Bristow MR; Billingham ME; Daniels JR
Cancer Treat Rep; 1978 Jun; 62(6):857-64. PubMed ID: 667859
[TBL] [Abstract][Full Text] [Related]
12. [Chronic toxicities of adriamycin (ADR) and their possible prevention by coenzyme Q10 and verapamil in rabbits--especially ADR induced cardiomyopathy (author's transl)].
Dohmae N; Sawada H; Tashima M; Uchino H; Matsuyama E; Konishi T
Nihon Gan Chiryo Gakkai Shi; 1979 Oct; 14(6):1009-28. PubMed ID: 541529
[No Abstract] [Full Text] [Related]
13. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
Gershanovich ML; Moiceenko VM; Orlova RV
Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis and prevention of doxorubicin cardiomyopathy.
Ferrans VJ; Clark JR; Zhang J; Yu ZX; Herman EH
Tsitologiia; 1997; 39(10):928-37. PubMed ID: 9505340
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
16. Delayed and progressive myocardial lesions after adriamycin administration in the rabbit.
Jaenke RS
Cancer Res; 1976 Aug; 36(8):2958-66. PubMed ID: 1277204
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy.
Singal PK; Siveski-Iliskovic N; Hill M; Thomas TP; Li T
J Mol Cell Cardiol; 1995 Apr; 27(4):1055-63. PubMed ID: 7563102
[TBL] [Abstract][Full Text] [Related]
18. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
[TBL] [Abstract][Full Text] [Related]
19. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
20. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
